Johnson & Johnson Reports 94% Success Rate in Clinical Trial for Shockwave Javelin Catheter
Johnson & Johnson (JNJ) has announced positive 30-day results from its FORWARD CAD clinical trial regarding the experimental Shockwave Javelin catheter. The device is specifically designed to treat severely narrowed coronary arteries that are traditionally difficult to access using conventional medical devices. The study reported a 94% success rate in reaching target lesions, marking a significant milestone for the company's cardiovascular intervention portfolio. If approved, this technology could expand treatment options for patients with complex coronary artery disease who currently face limited procedural success rates.
Tickers: $JNJ
Topics: clinical trial results coronary artery disease medical devices